Molecular genetics of von Willebrand disease;Molekulare genetik des von-Willebrand-Syndroms

Hamostaseologie

Volumn 24, Issue 1, 2004, Pages 37-43

  Schneppenheim, Reinhard ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Genetics; VWD; VWF

Indexed keywords

BLOOD CLOTTING FACTOR 8; GENE PRODUCT; VON WILLEBRAND FACTOR;

BLEEDING DISORDER; COMPLEX FORMATION; DISEASE CLASSIFICATION; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; MOLECULAR GENETICS; PATHOGENESIS; PHENOTYPE; POLYMERIZATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TRANSPORT; QUALITATIVE DIAGNOSIS; REVIEW; THROMBOSIS; TREATMENT PLANNING; VON WILLEBRAND DISEASE;

EID: 1242286001     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619604     Document Type: Review

References (41)

1. Allen S, Abuzenadah AM, Blagg JL et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 2000-7.
2. Allen S, Goodeve AC, Peake IR et al. Endoplasmic reticulum retention and prolonged association of a von Willebrand's disease-causing von Willebrand factor variant with ERp57 and calnexin. Biochem Biophys Res Commun 2001; 280: 448-53.
3. Baronciani L, Cozzi G, Canciani MT et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40.
4. Baronciani L, Cozzi G, Canciani MT et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-70.
5. Dent JA, Berkowitz SD, Ware J et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-10.
6. Eikenboom JC, Matsushita T, Reitsma PH et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88: 2433-41.
7. Enayat MS, Guilliatt AM, Surdhar GK et al. Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. Blood 2001; 98: 674-80.
8. Foster PA, Fulcher CA, Marti T et al. A major F VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
9. Fujimura Y, Titani K, Holland LZ et al. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262: 1734-9.
10. Gaucher C, Dieval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 1024-30.
11. Gaucher C, Jorieux S, Mercier B et al. The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937-41.
12. Ginsburg D, Konkle BA, Gill JC et al. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci USA 1989; 86: 3723-7.
13. Hilbert L, Jorieux S, Proulle V et al. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120: 627-32.
14. Hillery CA, Mancuso DJ, Evan Sadler J et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-81.
15. Jorieux S, Fressinaud E, Goudemand J et al. Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95: 3139-45.
16. Kalafatis M, Takahashi Y, Girma JP et al. Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365. Blood 1987; 70: 1577-83.
17. Ledford MR, Rabinowitz I, Sadler JE et al. New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood 1993; 82: 169-75.
18. Lyons SE, Bruck ME, Bowie EJW et al. Impaired intracellular transport produced by a subset of type-IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
19. Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and pseudogene: Structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253-69.
20. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
21. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992; 89: 3531-5.
22. Meyer D, Fressinaud E, Gaucher C et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997; 78: 451-6.
23. Ngo KY, Glotz VT, Koziol JA et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
24. Nishino M, Girma JP, Rothschild C et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
25. Ribba AS, Loisel I, Lavergne JM et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 848-54.
26. Saiki RK, Gelfand DH, Stoffel S et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-91.
27. Sakariassen KS, Fressinaud E, Girma JP et al. Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor. Blood 1986; 67: 1515-8.
28. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
29. Schneppenheim R, Brassard J, Krey S et al. Defective dimerization of von Willebrand factor subunits due to a Cys→Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 938: 3581-6.
30. Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N patients with suspected haemophilia A or van Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
31. Schneppenheim R, Budde U, Obser T et al. Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease. Blood 2001; 97: 2059-66.
32. Schneppenheim R, Gazda H, Budde U et al. A single base deletion (ΔC in exon 18 of the VWF gene) is the most common molecular defect in von Willebrand disease type 3 in countries surrounding the Baltic Sea. In: Herrmann FH (ed). Molekulare (DNA) Diagnostik hereditärer Hämostasedefekte. Lengerich: Pabst Science Publishers 1999; 91-6.
33. Schneppenheim R, Krey S, Bergmann F et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Human Genetics 1994; 94: 640-52.
34. Schneppenheim R, Obser T, Drewke E et al. Isolated molecular defects of von Willebrand factor binding to collagen do not correlate with bleeding symptoms. Blood 2001; 98 (suppl 1): 165.
35. Schneppenheim R, Obser T, Schneppenheim S et al. Von Willebrand disease type 2A with aberrant structure of individual oligomers is caused by mutations clustering in the von Willebrand factor D3 domain. Blood 2000; 96 (suppl 1): 2429.
36. Schneppenheim R, Thomas KB, Krey S et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 681-6.
37. Shelton-Inloes BB, Chehab FF, Mannucci PM et al. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-65.
38. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503-17.
39. Ware J, Dent JA, Azuma H et al. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci USA 1991; 887: 2946-50.
40. Zhang ZP, Falk G, Blomback M et al. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1: 767-8.
41. Zhang ZP, Lindstedt M, Falk G et al. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51: 850-8.